{"id":"naltrexone-oral-product","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Anxiety"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Joint and muscle pain"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naltrexone competitively binds to opioid receptors (mu, delta, and kappa) with highest affinity for mu receptors, preventing opioid agonists from activating these receptors. This mechanism is used to treat opioid use disorder by reducing cravings and blocking the rewarding effects of opioids, and also to treat alcohol use disorder through modulation of endogenous opioid signaling involved in reward pathways.","oneSentence":"Naltrexone is an opioid receptor antagonist that blocks the effects of opioids and endogenous opioid peptides in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:34.308Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder"},{"name":"Alcohol use disorder"}]},"trialDetails":[{"nctId":"NCT07224009","phase":"PHASE2","title":"Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)","status":"NOT_YET_RECRUITING","sponsor":"University of Arkansas","startDate":"2026-03","conditions":"Metastatic Prostate Cancer","enrollment":60},{"nctId":"NCT04276259","phase":"PHASE4","title":"Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2020-10-19","conditions":"Major Depressive Disorder, Depression","enrollment":120},{"nctId":"NCT07285473","phase":"PHASE2","title":"Low-Dose Naltrexone For ME/CFS: Dose-Finding","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Myalgic Encephalomyelitis/Chronic Fatigue Syndrome","enrollment":75},{"nctId":"NCT06845124","phase":"PHASE2","title":"A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence","status":"RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2025-07-22","conditions":"Alcohol Addiction, Alcoholism","enrollment":150},{"nctId":"NCT03482479","phase":"PHASE2","title":"Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-02-04","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis","enrollment":60},{"nctId":"NCT05579249","phase":"PHASE4","title":"A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-19","conditions":"Obesity","enrollment":500},{"nctId":"NCT04791969","phase":"PHASE2","title":"Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM","status":"COMPLETED","sponsor":"Glenn-Milo Santos","startDate":"2021-12-14","conditions":"Methamphetamine Use Disorder","enrollment":60},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT06809166","phase":"PHASE4","title":"Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity","status":"RECRUITING","sponsor":"The Royal's Institute of Mental Health Research","startDate":"2024-07-04","conditions":"Obesity, Weight Loss, Weight Management","enrollment":40},{"nctId":"NCT06140420","phase":"PHASE4","title":"Naltrexone for Prolonged Grief Disorder","status":"TERMINATED","sponsor":"Texas Tech University","startDate":"2023-08-01","conditions":"Naltrexone HCl 50 MG Oral Tablet, Placebo","enrollment":7},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT04678895","phase":"PHASE2","title":"Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2020-12-22","conditions":"Painful Diabetic Neuropathy","enrollment":35},{"nctId":"NCT05304364","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)","status":"COMPLETED","sponsor":"Delpor, Inc.","startDate":"2022-03-22","conditions":"Opiod Use Disorder","enrollment":10},{"nctId":"NCT05092841","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A","status":"COMPLETED","sponsor":"Tasly GeneNet Pharmaceuticals Co., Ltd","startDate":"2021-09-28","conditions":"Charcot-Marie-Tooth Type 1A","enrollment":176},{"nctId":"NCT05940324","phase":"PHASE2","title":"Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-02-24","conditions":"Obsessive-Compulsive Disorder","enrollment":150},{"nctId":"NCT02454712","phase":"PHASE1","title":"Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2016-11-16","conditions":"Healthy","enrollment":64},{"nctId":"NCT04531176","phase":"PHASE4","title":"EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-09-01","conditions":"Type 2 Diabetes, Obesity","enrollment":74},{"nctId":"NCT06426303","phase":"PHASE4","title":"Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder","status":"RECRUITING","sponsor":"Milky Kohno","startDate":"2024-05-02","conditions":"Alcohol Use Disorder","enrollment":100},{"nctId":"NCT04480554","phase":"PHASE2","title":"Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-01-30","conditions":"Opioid-use Disorder, HIV-1-infection, Immune Activation","enrollment":225},{"nctId":"NCT04553263","phase":"EARLY_PHASE1","title":"Relapse Prevention in Stimulant Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-06-11","conditions":"Stimulant Use, Relapse, Cognitive Function","enrollment":""},{"nctId":"NCT04589130","phase":"PHASE4","title":"Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.","status":"UNKNOWN","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2021-02-01","conditions":"Obesity","enrollment":89},{"nctId":"NCT04587843","phase":"PHASE4","title":"A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery","status":"UNKNOWN","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2021-04-01","conditions":"Obesity","enrollment":18},{"nctId":"NCT04756128","phase":"PHASE2","title":"Impact of Colchicine and Low-dose Naltrexone on COVID-19","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2021-01-25","conditions":"Covid19","enrollment":142},{"nctId":"NCT03374956","phase":"PHASE3","title":"Individualized Obesity Pharmacotherapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-12-11","conditions":"Obesity","enrollment":193},{"nctId":"NCT02268448","phase":"PHASE1","title":"Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2015-07","conditions":"Cutaneous Nerves CNS Itch","enrollment":8},{"nctId":"NCT03799198","phase":"PHASE4","title":"Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-07","conditions":"Obesity","enrollment":200},{"nctId":"NCT04139213","phase":"PHASE2, PHASE3","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"UNKNOWN","sponsor":"Lifespan","startDate":"2019-07-25","conditions":"Opioid-use Disorder","enrollment":250},{"nctId":"NCT01843023","phase":"PHASE4","title":"Extended Release Naltrexone for Opioid-Dependent Youth","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2013-06","conditions":"Drug Dependence","enrollment":288},{"nctId":"NCT03078075","phase":"PHASE3","title":"Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-05-05","conditions":"Methamphetamine Use Disorder","enrollment":403},{"nctId":"NCT01415895","phase":"PHASE2","title":"Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain","status":"COMPLETED","sponsor":"Annette C. Toledano MD","startDate":"2011-07","conditions":"Back Pain, Lower Back Pain, Cervical Pain","enrollment":78},{"nctId":"NCT02978417","phase":"PHASE4","title":"Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-09-21","conditions":"Opioid-Related Disorders","enrollment":14},{"nctId":"NCT02294253","phase":"PHASE2, PHASE3","title":"Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-09","conditions":"Opioid Dependence","enrollment":30},{"nctId":"NCT03678792","phase":"PHASE3","title":"Comparison of Three Opioid Detoxification Treatment Regimens","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2019-11-15","conditions":"Opioid-Related Disorders, Opioid Withdrawal","enrollment":""},{"nctId":"NCT03766893","phase":"EARLY_PHASE1","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"COMPLETED","sponsor":"Lifespan","startDate":"2018-09-01","conditions":"Opioid-use Disorder","enrollment":11},{"nctId":"NCT01101815","phase":"PHASE2","title":"Adherence to HIV Therapy in Heroin Addicts: Oral vs XR-NTX","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-06","conditions":"HIV, Substance Abuse, HIV Infections","enrollment":200},{"nctId":"NCT01746901","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02","conditions":"Healthy","enrollment":81},{"nctId":"NCT01717963","phase":"PHASE3","title":"Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway","status":"COMPLETED","sponsor":"University of Oslo","startDate":"2012-10","conditions":"Opioid Dependence","enrollment":166},{"nctId":"NCT00715117","phase":"PHASE2","title":"The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-07","conditions":"Crohn's Disease","enrollment":14},{"nctId":"NCT01739192","phase":"EARLY_PHASE1","title":"A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence","status":"COMPLETED","sponsor":"Craig Rush","startDate":"2013-01","conditions":"Cocaine Use Disorders","enrollment":34},{"nctId":"NCT01389167","phase":"PHASE3","title":"Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-09","conditions":"Opiate Dependence","enrollment":320},{"nctId":"NCT02726035","phase":"PHASE4","title":"Evaluation of Naltrexone as a Treatment for Self-injurious Behavior","status":"WITHDRAWN","sponsor":"Western Michigan University School of Medicine","startDate":"2014-02-22","conditions":"Self-injurious Behavior, Self Mutilation","enrollment":""},{"nctId":"NCT02446002","phase":"PHASE1","title":"Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy Subjects","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2015-05","conditions":"Healthy","enrollment":25},{"nctId":"NCT00976066","phase":"PHASE1","title":"[11C]Carfentanil PET Study of GSK1521498","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-15","conditions":"Obesity","enrollment":26},{"nctId":"NCT01571362","phase":"PHASE3","title":"A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Chronic Pain, Low Back Pain, Analgesia","enrollment":410},{"nctId":"NCT02638129","phase":"PHASE4","title":"Naltrexone/Bupropion Cardiovascular Outcomes Study","status":"TERMINATED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2016-01","conditions":"Obesity, Cardiovascular Diseases","enrollment":67},{"nctId":"NCT00733720","phase":"PHASE1","title":"Buprenorphine Naltrexone-P1 A-Cocaine","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2008-08","conditions":"Cocaine-related Disorders","enrollment":8},{"nctId":"NCT01218984","phase":"PHASE2","title":"ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2002-03","conditions":"Opiate Dependence","enrollment":27},{"nctId":"NCT02745912","phase":"PHASE1","title":"Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2016-04","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT02616315","phase":"PHASE4","title":"Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2016-02","conditions":"Weight Regain Post Bariatric Surgery","enrollment":""},{"nctId":"NCT02117583","phase":"PHASE1","title":"Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":34},{"nctId":"NCT02165930","phase":"PHASE1","title":"Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-07","conditions":"Healthy","enrollment":17},{"nctId":"NCT02089295","phase":"PHASE1","title":"Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":18},{"nctId":"NCT02059915","phase":"PHASE1","title":"Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":134},{"nctId":"NCT01462227","phase":"NA","title":"Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-08","conditions":"Hypoglycemia","enrollment":17},{"nctId":"NCT01015547","phase":"PHASE3","title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2003-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT01717027","phase":"PHASE1","title":"Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-11","conditions":"Healthy","enrollment":19},{"nctId":"NCT01924676","phase":"PHASE1","title":"Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2013-08","conditions":"Healthy","enrollment":18},{"nctId":"NCT01552863","phase":"PHASE1","title":"A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-03","conditions":"Pain","enrollment":21},{"nctId":"NCT01015066","phase":"PHASE4","title":"Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents","status":"WITHDRAWN","sponsor":"State University of New York at Buffalo","startDate":"2009-11","conditions":"Opiate Addiction","enrollment":""},{"nctId":"NCT00105482","phase":"PHASE2","title":"Targeted Interventions for Weight-Concerned Smokers","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-01","conditions":"Nicotine Dependence","enrollment":172},{"nctId":"NCT01327326","phase":"NA","title":"Role of the Endogenous Opioid System Underlying Modulation of Experimental Pain","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2011-12","conditions":"Temporomandibular Disorder, Facial Pain","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Naltrexone Oral Product","genericName":"Naltrexone Oral Product","companyName":"Texas Tech University","companyId":"texas-tech-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naltrexone is an opioid receptor antagonist that blocks the effects of opioids and endogenous opioid peptides in the central nervous system. Used for Opioid use disorder, Alcohol use disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}